News from EAS 2024: Plozasiran in mixed hyperlipidemia

Encouraging data with APOC3 siRNA in mixed hyperlipidemia

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Long-term efficacy and safety data of lomitapide in HoFH
Long-term efficacy and safety data of lomitapide in HoFH
EAS 2024
Long-term efficacy and safety data of lomitapide in HoFH
- Dirk Blom, PhD
Exciting times to address residual inflammatory risk
Exciting times to address residual inflammatory risk
EAS 2024
Exciting times to address residual inflammatory risk
- Peter Libby, MD
Causal relationship between elevated Lp(a) levels and CKD risk
Causal relationship between elevated Lp(a) levels and CKD risk
EAS 2024
Causal relationship between elevated Lp(a) levels and CKD risk
- Anne Langsted, MD, PhD
Rationale for dietary fat recommendations in ASCVD prevention
Rationale for dietary fat recommendations in ASCVD prevention
EAS 2024
Rationale for dietary fat recommendations in ASCVD prevention
- Jacob J. Christensen, PhD